IL‐11 in cardiac and renal fibrosis: Late to the party but a central player
Citations Over TimeTop 10% of 2020 papers
Abstract
Fibrosis is a pathophysiological hallmark of cardiorenal disease. In the heart, fibrosis leads to contractile dysfunction and arrhythmias; in the kidney, it is the final common pathway for many diseases and predicts end-stage renal failure. Despite this, there are currently no specific anti-fibrotic treatments available for cardiac or renal disease. Recently and unexpectedly, IL-11 was found to be of major importance for cardiorenal fibroblast activation and fibrosis. In mouse models, IL-11 overexpression caused fibrosis of the heart and kidney while genetic deletion of Il11ra1 protected against fibrosis and preserved organ function. Neutralizing antibodies against IL-11 or IL-11RA have been developed that have anti-fibrotic activity in human fibroblasts and protect against fibrosis in murine models of disease. While IL-11 biology has been little studied and, we suggest, largely misunderstood, its autocrine activity in myofibroblasts appears non-redundant for fibrosis, which offers new opportunities to better understand and potentially target cardiorenal fibrosis.
Related Papers
- → lncRNA SRA1 Promotes the Activation of Cardiac Myofibroblasts Through Negative Regulation of miR-148b(2019)17 cited
- → Pro-fibrotic effect of oxidized LDL in cardiac myofibroblasts(2020)17 cited
- Abstract 262: Myofibroblast-Specific Transforming Growth Factor β Suppression Reduces Fibrosis in a Proteotoxic CryabR120g Mouse Model of Heart Failure(2017)
- → Mechanosensitive TRPV4 channels mediate cardiac fibroblast differentitation to myofibroblasts(2012)
- → Abstract 262: Myofibroblast-Specific Transforming Growth Factor β Suppression Reduces Fibrosis in a Proteotoxic Cryab R120g Mouse Model of Heart Failure(2017)